Reclast, also known by its generic name zoledronic acid, was first approved by the U.S. Food and Drug Administration (FDA) in October 2001 [1].
When was Reclast first approved for osteoporosis?
While zoledronic acid received its initial FDA approval in 2001 for treating hypercalcemia of malignancy, its approval for osteoporosis in postmenopausal women came later [1]. It was approved for this indication in August 2007 [2].
What other conditions is Reclast used for?
Beyond postmenopausal osteoporosis, Reclast is also approved for [2, 3]:
* Treating Paget's disease of bone
* Increasing bone mass in men with osteoporosis
* Treating men and women with osteoporosis who are also taking corticosteroids
* Preventing skeletal-related events in patients with bone metastases from solid tumors
How does Reclast work?
Reclast belongs to a class of drugs called bisphosphonates. It works by slowing down bone loss, which helps to maintain bone density and reduce the risk of fractures [4].
What is the typical treatment duration for Reclast?
The recommended treatment duration for Reclast can vary depending on the condition being treated and individual patient factors. For postmenopausal osteoporosis, it is often administered once a year intravenously [2]. However, the optimal duration of treatment and the need for continuation or discontinuation should be determined by a healthcare provider [4].
What are the potential risks associated with Reclast?
Like other bisphosphonates, Reclast carries potential risks that patients and healthcare providers should be aware of. These can include [5]:
* Kidney problems
* Osteonecrosis of the jaw (ONJ), a rare but serious condition affecting the jawbone
* Atypical femur fractures, which are breaks in the thigh bone that can occur with little or no trauma
Has Reclast had patent challenges?
Information regarding specific patent challenges for Reclast is available through resources that track drug patents and litigation. DrugPatentWatch.com provides data on pharmaceutical patents and can be a source for such details [6].